(Total Views: 642)
Posted On: 05/20/2022 6:55:29 AM
Post# of 148870
Here is a nice short one:
Playing Dead
The kisses of an enemy deceive.
The suffering of a friend captivates.
Where does our next new base of knowledge come from? From where does knowledge increase? How well did we do in NASH 700? The late June conference quickly approaches. What are the implications should NASH 700 reveals that 50% of the patients had a 160ms drop in cT1. Only that it would equate to a 7 - 8 point drop in NAS score. Since worst cast of NASH = NAS of 8, then, in 50% of patients, Leronlimab would be capable of reducing the worst case of NASH to grade 1 NAS or healthy liver.
What if 80% of the patients had a 100ms drop in cT1? That would mean that in 80% of the patients, LL drops NASH by 5 NAS points, taking a patient with NAS of 8 to NAS of 3 or a patient with NAS of 5 to healthy liver. 80% of patients. Could it be?
If what I just wrote is true, then information of this caliber is equivalent to partnership. A question I raise. How long has this information been known? Well, it has been known prior to Nader's termination. Where am I going with this? I say CytoDyn has been playing dead for months already, when in fact, they are very much alive.
Wake up people. We were given knowledge of 350mg NASH as fodder. We were given knowledge of mTNBC Overall Survivability of 12 months as fodder. In mTNBC, the drug has been continuously dosed as per schedule even past November. In NASH, we doubled the dose. Knowledge of mTNBC OS comes in mid June, about a month from now. Late June brings the NASH 700 data.
CytoDyn already knows the results. So do the partners.
CytoDyn is playing dead.
Playing Dead
The kisses of an enemy deceive.
The suffering of a friend captivates.
Where does our next new base of knowledge come from? From where does knowledge increase? How well did we do in NASH 700? The late June conference quickly approaches. What are the implications should NASH 700 reveals that 50% of the patients had a 160ms drop in cT1. Only that it would equate to a 7 - 8 point drop in NAS score. Since worst cast of NASH = NAS of 8, then, in 50% of patients, Leronlimab would be capable of reducing the worst case of NASH to grade 1 NAS or healthy liver.
What if 80% of the patients had a 100ms drop in cT1? That would mean that in 80% of the patients, LL drops NASH by 5 NAS points, taking a patient with NAS of 8 to NAS of 3 or a patient with NAS of 5 to healthy liver. 80% of patients. Could it be?
If what I just wrote is true, then information of this caliber is equivalent to partnership. A question I raise. How long has this information been known? Well, it has been known prior to Nader's termination. Where am I going with this? I say CytoDyn has been playing dead for months already, when in fact, they are very much alive.
Wake up people. We were given knowledge of 350mg NASH as fodder. We were given knowledge of mTNBC Overall Survivability of 12 months as fodder. In mTNBC, the drug has been continuously dosed as per schedule even past November. In NASH, we doubled the dose. Knowledge of mTNBC OS comes in mid June, about a month from now. Late June brings the NASH 700 data.
CytoDyn already knows the results. So do the partners.
CytoDyn is playing dead.
(15)
(0)Scroll down for more posts ▼
